A double-blind, placeho-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 2, Issue 1, 2001, Pages 9-18

  Desnuelle, Claude ^a   Dib, Michel ^b   Garrel, Catherine ^c   Favier, Alain ^c  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b SANOFI   (France)

^c HÔPITAL MICHALLON   (France)

Author keywords

Tocopherol; ALS; Clinical trial; Health states; Malondialdehyde; Norris scale; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; BIOCHEMICAL MARKER; GLUTATHIONE PEROXIDASE; PLACEBO; RILUZOLE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DYSPHAGIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EVIDENCE BASED MEDICINE; FAMILIAL DISEASE; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MOTOR PERFORMANCE; MOUSE; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PARALYSIS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SURVIVAL; TRANSGENIC MOUSE; TREATMENT OUTCOME; BLOOD; DRUG EFFECT; ENZYMOLOGY; FOLLOW UP; METABOLISM; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROLOGIC EXAMINATION;

AGED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROLOGIC EXAMINATION; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TREATMENT OUTCOME; VITAMIN E;

EID: 0035007860     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/146608201300079364     Document Type: Article

References (37)

1. Williams DB, Windebank AJ. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc 1991; 66: 54-82.
2. Norris F, Shepherd R, Denys E et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118: 48-55.
3. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J Neurol 1997; 244 (Suppl 2): S3-S14.
4. Cookson MR, Shaw PJ. Oxidative stress and motor neurone disease. Brain Pathol 1999; 9: 165-186.
5. Beal MF, Ferrante RJ, Browne SE et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 1997; 42: 646-654.
6. Ferrante RJ, Browne SE, Shinobu LA et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997; 69: 2064-2074.
7. Przedborski S, Donaldson DM, Murphy PL et al. Blood superoxide dismutase, catalase and glutathione peroxidase activities in familial and sporadic amyotrophic lateral sclerosis. Neurodegeneration 1996; 5: 57-64.
8. Apostolski S, Marinkovic Z, Nikolic A et al. Glutathione peroxidase in amyotrophic lateral sclerosis: the effect of selenium supplementation. J Environ Pathol 1998; 17: 325-329.
9. Moumen R, Nouvelot A, Duval D et al. Plasma superoxide dismutase and glutathione peroxidase activity in sporadic amyotrophic lateral sclerosis. J Neurol Sci 1997; 151: 35-39.
10. Vielhaber S, Kunz D, Winkler K et al. Mitochondrial DNA abnormalities in skeletal musde of patients with amyotrophic lateral sclerosis. Brain 2000; 123: 1339-1348.
11. Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
12. Corson LB, Strain JJ, Culotta VC, Cleveland DW. Chaperone-facilitated copper binding is a property common to several classes of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants. Proc Natl Acad Sci USA 1998; 95: 6361-6366.
13. Gurney ME, Cutting FB, Zhai P et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-157.
14. Favier AE. How to demonstrate the occurrence of an oxidative stress in humans? In: Favier AE et al, eds. Analysis of Free Radicals in Biological Systems. Basel: Birkhauser Verlag, 1995: 99-117.
15. Shoulson I for the Parkinson Study Group. DATATOP: a decade of neuroprotective enquiry. Ann Neurol 1998; 44 (Suppl): S160-S166.
16. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1216-1222.
17. Norris FH, Denys EH. Nutritional supplements in amyotrophic lateral sclerosis. Adv Exp Med Biol 1987; 209: 183-189.
18. Diplock AT. Safety of antioxidant vitamins and β-carotene. Am J Clin Nutr 1995; 62 (Suppl): 1510S-1516S.
19. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci, 1994; 124 (Suppl): 96-107.
20. Norris FH, Calanchini PR, Fallat RH et al. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974; 24: 721-728.
21. Lacomblez L, Bouche P, Bensimon G, Meininger V. A double-blind placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology 1989; 39: 1635-1637.
22. Bensimon G, Lacomblez L, Meininger V and the ALS/Riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994; 330: 585-591.
23. Lacomblez L, Bensimon G, Leigh PN et al. Dose ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-1431.
24. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Medical Care 1981; 19: 787-805.
25. Rivière M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55: 526-528.
26. Munsat TL for the World Federation of Neurology Research Group on Neuromuscular Diseases Subcommittee on Motor Neuron Disease. Airlie House Guidelines. Therapeutic trials in amyotrophic lateral sclerosis. J Neurol Sci 1995; 129 (Suppl): 1-10.
27. Richard MJ, Portal B, Meo J et al. Malondialdehyde kit evaluated for determining plasma and lipoprotein fractions that react with thiobarbituric add. Clin Chem 1992; 38: 704-709.
28. Marklund S, Marklund G. Involvement of superoxide anion radical in the auto-oxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1996; 47: 469-474.
29. Gunzler WA, Kremers H, Flobe L. An improved coupled test procedure for glutathione peroxidase in blood. Z Clin Chem Klin Biochem 1974; 12: 444-448.
30. Steghens JP, Van Kappel AL, Riboli E, Colombel C. Simultaneous measurement of seven carotenoids, retinol and α-tocopherol in serum by high performance liquid chromatography. J Chromatography 1991; 694: 71-81.
31. Sappey C, Ledercq P, Coudray C et al. Vitamins, trace elements and peroxide status in HIV seropositive patients: asymptomatic patients present a severe β-carotene deficiency. Clin Chim Acta 1994; 230: 35-42.
32. Hercherg S, Galan P, Roussel AM et al. Background and rationale behind the SU.VI.MAX study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. Int J Vit Nutri Res 1998; 68: 3-20.
33. Oteiza PI, Uchitel OD, Carrasquedo F et al. Evaluation of antioxidants, protein and lipid oxidation in blood from sporadic amyotrophic lateral sclerosis patients. Neurochem Res 1997; 22: 535-539.
34. Colton C, Yao J, Grossman Y, Gilbert D. The effect of xanthine/xanthine oxidase generated reactive oxygen species on synaptic transmission. Free Rad Res Comm 1991; 14: 385-393.
35. Sies H, Sharov V, Klotz LO, Brivida K. Glutathione peroxidase protects against peroxynitrite-mediated oxidations. J Biol Chem 1997; 272: 27812-27817.
36. Pigeolet E, Corbisier P, Houbion A et al. Glutathione peroxidase, superoxide dismutase, and catalase inactivation by peroxides and oxygen derived free radicals. Mech Ageing Dev 1990; 51: 283-297.
37. Vatassery GT, Fahn S, Kuskowski MA. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology 1998; 50: 1900-1902.